CPM-LAD, or CYPM-LAD, also known as 6-(cyclopropylmethyl)-6-nor-LSD, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family. Example 13: Preparation of (6aR,9R)-N,N-diethyl-7-(cyclopropylmethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (13) [...] It is the analogue of LSD in which the methyl group at the 6 position has been replaced with a cyclopropylmethyl group.
Use and effects Unlike related lysergamides, CPM-LAD was not mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved) and is not known to have been tested in humans.
Interactions
Pharmacology Pharmacodynamics CPM-LAD showed affinity (Ki) values for serotonin receptors of 10.9nM for serotonin-labeled 5-HT1 receptors and 7.7nM for ketanserin-labeled 5-HT2 receptors. These affinities were very similar to but slightly lower than those of LSD. CPM-LAD fully substituted for LSD in rodent drug discrimination tests with an of 0.067μmol/kg, relative to a dose of 0.046μmol/kg in the case of LSD (with CPM-LAD about 1.5-fold less potent than LSD). Additional pharmacology for CPM-LAD has also been published.
History CPM-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1987. Subsequently, it was patented by Gilgamesh Pharmaceuticals in 2022, who further studied and described its pharmacology. Derivatives of CPM-LAD have also been patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed.
Society and culture Legal status Canada CPM-LAD is not a controlled substance in Canada as of 2025.
See also Substituted lysergamide CYP-LAD
References
External links CYPM-LAD - Isomer Design